Increasing prevalence of obesity and type 2 diabetes (T2D) [Figure 1](#F1){ref-type="fig"} around the globe, creating higher risk for cardiovascular diseases (CVDs) and increasing strain on health care budget of every country in the world \[[@R1]\]. This is because of unavailability of successful preventive/ therapeutic strategies against these health ailments. The reason behind this problem is the complex pathophysiology of obesity and T2D \[[@R2]\]. Various factors i.e. genetics, environmental factors and diet plays an important role in development of obesity and progression of its life threatening complications i.e. insulin resistance (T2D) and CVDs, through modulation of various fundamental metabolic pathways i.e. food intake, lipid metabolism (hyperlipidemia), oxidative stress and immune system (inflammation) \[[@R3]\]. Recently, role of gut-flora in development of obesity and T2D got tremendous attention among scientific community and has been considered one the potential therapeutical targets against obesity and diabetes \[[@R4]--[@R6]\]. Probiotics are potential modulators of gut-flora that changes gut-flora composition in a beneficial manner and exerts various health beneficial effects i.e. anti-hyperlipidemic, anti-oxidant and anti-inflammatory \[[@R7]\]. But the consumption of probiotics for human is cautioned and highly debatable in terms of development of obesity and weight gain. Here we will discuss few points and scientific findings/ reasons about how probiotics can be used as a biotherapeutical agent against obesity and diabetes.

This concerned arisen for probiotic consumption in the report of Dr. Raoult \[[@R8]\] that was on the basis of animal data, where sick animals treated with probiotics start gaining weight rapidly after probiotic treatment \[[@R9],[@R10]\]. But there are no evidences suggest that animals treated with probiotics became obese/ diabetic. Our previous studies suggested that feeding of probiotic supplemented milk product (dahi/ yogurt) suppressed progression of diet induced T2D [Figure 1](#F1){ref-type="fig"} and metabolic derangements \[[@R11],[@R12]\]. In addition, our ongoing study also suggested (un-published data) that consumption of probiotic formulations dramatically suppressed obesity and diabetes in high fat diet fed mice and reduced food intake. This suggests that, consumption of probiotics is not deleterious for progression of obesity and T2D. However, these evidences doesn't exclude the differential efficacy of probiotics in human subjects, hence very well controlled/ designed studies are urgently needed to check the efficacy of probiotics in human health against obesity and diabetes. A deeper knowledge of our gut ecology will be mandatory in the hope to target much more specific probiotic intervention. In this regards it is of interest the recent intriguing review from Rastmanesh \[[@R13]\] suggesting that a high-polyphenol and selectively-restricted probiotic diet could represent a novel strategy for planning a successful dietary regimen and/or neutraceutical/ pharmaceutical preparations to achieve and maintain a normal body weight in obese individuals. Overall, such studies will also give opportunities to industries to think about the risk vs safety of probiotic formulations for obesity and diabetes in consumers, worldwide.
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